APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Metachromatic Leukodystrophy (MLD) Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metachromatic Leukodystrophy (MLD) Treatment Market Outlook and Growth Opportunities 2026

Report ID 174012480422 December 2025193 pages

Choose your research edition.

Industry ResearchMetachromatic Leukodystrophy (MLD) Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Metachromatic Leukodystrophy (MLD) Treatment Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Metachromatic Leukodystrophy (MLD) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metachromatic Leukodystrophy (MLD) Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metachromatic Leukodystrophy (MLD) Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metachromatic Leukodystrophy (MLD) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metachromatic Leukodystrophy (MLD) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metachromatic Leukodystrophy (MLD) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metachromatic Leukodystrophy (MLD) Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metachromatic Leukodystrophy (MLD) Treatment market include Takeda, GlaxoSmithKline Plc, RegenxBio Inc, Recursion Pharmaceuticals Inc and ArmaGen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metachromatic Leukodystrophy (MLD) Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metachromatic Leukodystrophy (MLD) Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metachromatic Leukodystrophy (MLD) Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metachromatic Leukodystrophy (MLD) Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Metachromatic Leukodystrophy (MLD) Treatment Segment by Company

Takeda

GlaxoSmithKline Plc

RegenxBio Inc

Recursion Pharmaceuticals Inc

ArmaGen Inc

Metachromatic Leukodystrophy (MLD) Treatment Segment by Type

AGT-183

DUOC-01

GSK-2696274

Others

Metachromatic Leukodystrophy (MLD) Treatment Segment by Application

Hospital

Clinic

Others

Metachromatic Leukodystrophy (MLD) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Metachromatic Leukodystrophy (MLD) Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Metachromatic Leukodystrophy (MLD) Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metachromatic Leukodystrophy (MLD) Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Metachromatic Leukodystrophy (MLD) Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metachromatic Leukodystrophy (MLD) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metachromatic Leukodystrophy (MLD) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metachromatic Leukodystrophy (MLD) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metachromatic Leukodystrophy (MLD) Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metachromatic Leukodystrophy (MLD) Treatment industry.

Chapter 3: Detailed analysis of Metachromatic Leukodystrophy (MLD) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Metachromatic Leukodystrophy (MLD) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Metachromatic Leukodystrophy (MLD) Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metachromatic Leukodystrophy (MLD) Treatment Industry Trends Table 2. Metachromatic Leukodystrophy (MLD) Treatment Industry Drivers Table 3. Metachromatic Leukodystrophy (MLD) Treatment Industry Opportunities and Challenges Table 4. Metachromatic Leukodystrophy (MLD) Treatment Industry Restraints Table 5. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Company (2021-2026) Table 7. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Company (k units) & (2021-2026) Table 8. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Metachromatic Leukodystrophy (MLD) Treatment Average Price (US$/unit) of Company (2021-2026) Table 10. Global Metachromatic Leukodystrophy (MLD) Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Metachromatic Leukodystrophy (MLD) Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Metachromatic Leukodystrophy (MLD) Treatment Company, Product Type & Application Table 13. Global Metachromatic Leukodystrophy (MLD) Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Metachromatic Leukodystrophy (MLD) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of AGT-183 Table 18. Significant Companies of DUOC-01 Table 19. Significant Companies of GSK-2696274 Table 20. Significant Companies of Others Table 21. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Type (2021-2026) & (k units) Table 23. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Type (2027-2032) & (k units) Table 24. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Type (2021-2026) Table 25. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Type (2027-2032) Table 26. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type (2021-2026) Table 30. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Application (2021-2026) & (k units) Table 36. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Application (2027-2032) & (k units) Table 37. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Application (2021-2026) Table 38. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Application (2027-2032) Table 39. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application (2021-2026) Table 43. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application (2027-2032) Table 44. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2026) & (k units) Table 46. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2021-2026) Table 47. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2027-2032) & (k units) Table 48. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2027-2032) Table 49. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Region (2021-2026) Table 52. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Region (2027-2032) Table 54. Global Metachromatic Leukodystrophy (MLD) Treatment Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Metachromatic Leukodystrophy (MLD) Treatment Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 59. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2021-2026) Table 60. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2027-2032) & (k units) Table 61. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2027-2032) Table 62. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Market Share by Country (2021-2026) Table 64. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Market Share by Country (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 70. Takeda Recent Development Table 71. GlaxoSmithKline Plc Company Information Table 72. GlaxoSmithKline Plc Business Overview Table 73. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 75. GlaxoSmithKline Plc Recent Development Table 76. RegenxBio Inc Company Information Table 77. RegenxBio Inc Business Overview Table 78. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 80. RegenxBio Inc Recent Development Table 81. Recursion Pharmaceuticals Inc Company Information Table 82. Recursion Pharmaceuticals Inc Business Overview Table 83. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 85. Recursion Pharmaceuticals Inc Recent Development Table 86. ArmaGen Inc Company Information Table 87. ArmaGen Inc Business Overview Table 88. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 90. ArmaGen Inc Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Metachromatic Leukodystrophy (MLD) Treatment Distributors List Table 94. Metachromatic Leukodystrophy (MLD) Treatment Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Metachromatic Leukodystrophy (MLD) Treatment Product Image Figure 2. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (2021-2032) & (k units) Figure 5. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Metachromatic Leukodystrophy (MLD) Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. AGT-183 Image Figure 10. DUOC-01 Image Figure 11. GSK-2696274 Image Figure 12. Others Image Figure 13. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Type (2021-2032) Figure 16. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Application (2021-2032) Figure 25. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application (2021-2032) Figure 28. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. South America Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Metachromatic Leukodystrophy (MLD) Treatment Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Metachromatic Leukodystrophy (MLD) Treatment Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • AGT-183
  • DUOC-01
  • GSK-2696274
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda
  • GlaxoSmithKline Plc
  • RegenxBio Inc
  • Recursion Pharmaceuticals Inc
  • ArmaGen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Metachromatic Leukodystrophy (MLD) Treatment Market Dynamics
  1. 2.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Trends
  2. 2.2 Metachromatic Leukodystrophy (MLD) Treatment Industry Drivers
  3. 2.3 Metachromatic Leukodystrophy (MLD) Treatment Industry Opportunities and Challenges
  4. 2.4 Metachromatic Leukodystrophy (MLD) Treatment Industry Restraints
3 Metachromatic Leukodystrophy (MLD) Treatment Market by Company
  1. 3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Metachromatic Leukodystrophy (MLD) Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Metachromatic Leukodystrophy (MLD) Treatment Company Ranking (2024-2026)
  6. 3.6 Global Metachromatic Leukodystrophy (MLD) Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Metachromatic Leukodystrophy (MLD) Treatment Company Product Type and Application
  8. 3.8 Global Metachromatic Leukodystrophy (MLD) Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Metachromatic Leukodystrophy (MLD) Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Metachromatic Leukodystrophy (MLD) Treatment Market by Type
  1. 4.1 Metachromatic Leukodystrophy (MLD) Treatment Type Introduction
  2. 4.1.1 AGT-183
  3. 4.1.2 DUOC-01
  4. 4.1.3 GSK-2696274
  5. 4.1.4 Others
  6. 4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Type
  7. 4.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Type
  11. 4.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Type (2021-2032)
  13. 4.3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type (2021-2032)
5 Metachromatic Leukodystrophy (MLD) Treatment Market by Application
  1. 5.1 Metachromatic Leukodystrophy (MLD) Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Application
  6. 5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Application
  10. 5.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application (2021-2032)
6 Metachromatic Leukodystrophy (MLD) Treatment Regional Sales and Value Analysis
  1. 6.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2027-2032)
  5. 6.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Metachromatic Leukodystrophy (MLD) Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Country, 2025 VS 2032
7 Metachromatic Leukodystrophy (MLD) Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2027-2032)
  6. 7.4 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Metachromatic Leukodystrophy (MLD) Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Metachromatic Leukodystrophy (MLD) Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 RegenxBio Inc
  14. 8.3.1 RegenxBio Inc Company Information
  15. 8.3.2 RegenxBio Inc Business Overview
  16. 8.3.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  18. 8.3.5 RegenxBio Inc Recent Developments
  19. 8.4 Recursion Pharmaceuticals Inc
  20. 8.4.1 Recursion Pharmaceuticals Inc Company Information
  21. 8.4.2 Recursion Pharmaceuticals Inc Business Overview
  22. 8.4.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  24. 8.4.5 Recursion Pharmaceuticals Inc Recent Developments
  25. 8.5 ArmaGen Inc
  26. 8.5.1 ArmaGen Inc Company Information
  27. 8.5.2 ArmaGen Inc Business Overview
  28. 8.5.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  30. 8.5.5 ArmaGen Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metachromatic Leukodystrophy (MLD) Treatment Value Chain Analysis
  2. 9.1.1 Metachromatic Leukodystrophy (MLD) Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metachromatic Leukodystrophy (MLD) Treatment Sales Mode & Process
  6. 9.2 Metachromatic Leukodystrophy (MLD) Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metachromatic Leukodystrophy (MLD) Treatment Distributors
  9. 9.2.3 Metachromatic Leukodystrophy (MLD) Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst